Professional Seasonal Analysis for Trading

Cyclerion Therapeutics, Inc. - Common Stock (CYCN)

Seasonality Analysis

Stocks 8 Years Analyzed

Cyclerion Therapeutics, Inc. - Common Stock Annual Seasonality Statistics

-22.61%
Avg Annual Return
42.0%
Avg Monthly Win Rate
5/12
Positive Months
8
Years Analyzed

Cyclerion Therapeutics, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January 1.75%
71%
Strong
February -3.97%
57%
Weak
March -1.88%
50%
Weak
April -11.08%
25%
Very Weak
May -2.28%
29%
Very Weak
June 4.81%
43%
Weak
July 0.46%
29%
Weak
August BEST 11.99%
71%
Very Strong
September -0.13%
29%
Very Weak
October WORST -31.66%
14%
Very Weak
November -0.12%
29%
Very Weak
December 9.49%
57%
Moderate

Cyclerion Therapeutics, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
36.32
Historical Avg Position
38.27
Deviation
-1.95
Performance
On Track

Cyclerion Therapeutics, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for CYCN with overlay patterns, custom date ranges, and more.

Create Free Account

Cyclerion Therapeutics, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Cyclerion Therapeutics, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for CYCN across multiple timeframes.

Create Free Account

About Cyclerion Therapeutics, Inc. - Common Stock (CYCN) Seasonality

Cyclerion Therapeutics, Inc. - Common Stock (CYCN) has been analyzed using 8 years of historical data to identify seasonal patterns. Classified under Stocks, Cyclerion Therapeutics, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Cyclerion Therapeutics, Inc. - Common Stock is historically August, with an average return of 11.99% and a win rate of 71%. Conversely, October tends to be the weakest month, averaging -31.66% return.

Looking at the full calendar year, Cyclerion Therapeutics, Inc. - Common Stock has an average annual return of -22.61% with an overall monthly win rate of 42.0%. Out of 12 months, 5 typically show positive average returns.

The seasonal pattern for Cyclerion Therapeutics, Inc. - Common Stock has a consistency score of 70.3 (Very Good), based on 8 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Cyclerion Therapeutics, Inc. - Common Stock Seasonality FAQ

What is the best month to buy Cyclerion Therapeutics, Inc. - Common Stock (CYCN)?

Historically, August has been the best month for Cyclerion Therapeutics, Inc. - Common Stock, with an average return of 11.99% and a win rate of 71%. However, past performance does not guarantee future results.

What is the worst month for Cyclerion Therapeutics, Inc. - Common Stock (CYCN)?

Based on historical data, October has been the weakest month for Cyclerion Therapeutics, Inc. - Common Stock, with an average return of -31.66%. This is a historical observation and does not guarantee future results.

How reliable is CYCN seasonality data?

The seasonality analysis for Cyclerion Therapeutics, Inc. - Common Stock is based on 8 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Cyclerion Therapeutics, Inc. - Common Stock seasonality in my trading?

Use Cyclerion Therapeutics, Inc. - Common Stock (CYCN) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.